• OPEN AN ACCOUNT
Indian Indices
Nifty
24,946.50 227.90
(0.92%)
Sensex
81,583.30 -212.85
( -0.26%)
Bank Nifty
55,944.90 417.55
( 0.75%)
Nifty IT
39,073.05 603.80
( 1.57%)
Global Indices
Nasdaq
42,540.48 321.68
(0.76%)
Dow Jones
6,054.14 56.17
(0.94%)
Hang Seng
38,529.66 218.33
(0.57%)
Nikkei 225
8,875.22 24.59
(0.28%)
Forex
USD-INR
85.72 0.17
(0.19%)
EUR-INR
98.97 0.08
(0.08%)
GBP-INR
116.32 0.08
(0.07%)
JPY-INR
0.59 0.00
(-0.14%)

EQUITY - MARKET SCREENER

Divine Power Energy Ltd
Industry :  Mining / Minerals / Metals
BSE Code
ISIN Demat
Book Value()
92765
INE0SCO01019
36.2191417
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DPEL
37.95
347.21
EPS(TTM)
Face Value()
Div & Yield %
3.85
10
0
 

exide industries ltd
Lupin gets USFDA nod for Oxcarbazepine ER tablets
Jun 09,2025
Oxcarbazepine ER tablets, 150 mg, 300 mg, and 600 mg are bioequivalent to Oxtellar XR ER tablets, 150 mg, 300 mg, and 600 mg, of Supernus Pharmaceuticals, Inc., and are indicated for the treatment of partial-onset seizures in patients 6 years of age and older.

This product would be manufactured at Lupin’s Nagpur facility in India.

Oxcarbazepine ER tablets (RLD Oxtellar XR) had estimated annual sales of $206 million in the U.S. (IQVIA MAT April 2025).

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company’s consolidated net profit surged 114.9% to Rs 772.52 crore on 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24.

The scrip rose 0.20% to end at Rs 1,999.20 on the BSE.